Bacterial pathogens have evolved specific effector proteins that, by interfacing with host kinase signalling pathways, provide a mechanism to evade immune responses during infection 1, 2 . Although these effectors contribute to pathogen virulence, we realized that they might also serve as valuable synthetic biology reagents for engineering cellular behaviour. Here we exploit two effector proteins, the Shigella flexneri OspF protein 3 and Yersinia pestis YopH protein 4 , to rewire kinase-mediated responses systematically both in yeast and mammalian immune cells. Bacterial effector proteins can be directed to inhibit specific mitogen-activated protein kinase pathways selectively in yeast by artificially targeting them to pathway-specific complexes. Moreover, we show that unique properties of the effectors generate new pathway behaviours: OspF, which irreversibly inactivates mitogen-activated protein kinases 4 , was used to construct a synthetic feedback circuit that shows novel frequency-dependent input filtering. Finally, we show that effectors can be used in T cells, either as feedback modulators to tune the T-cell response amplitude precisely, or as an inducible pause switch that can temporarily disable T-cell activation. These studies demonstrate how pathogens could provide a rich toolkit of parts to engineer cells for therapeutic or biotechnological applications.
Many bacterial pathogens have developed an array of effector proteins to rewire host signalling networks and downregulate the immune response 2 (Fig. 1a ). Some effectors mimic host activities, such as the Y. pestis effector YopH, which is a highly active phosphotyrosine phosphatase 3 . Other effectors use unusual mechanisms, such as the S. flexneri OspF protein, which irreversibly inactivates mitogenactivated protein kinases (MAPKs) by catalysing a b-elimination reaction that removes the hydroxyl group of the key phosphothreonine side chain 4 .
MAPK pathways have a central role in diverse eukaryotic responses, ranging from immune response to cell-fate decisions 5, 6 . Thus, the ability to tune MAPK response would facilitate engineering cells for diverse therapeutic and biotechnological applications 7, 8 . Recent work has shown that MAPK signalling dynamics in yeast can be reshaped with synthetic feedback loops that involve controlled expression and targeting of pathway modulators to appropriate signalling complexes 9 . Identifying effective pathway modulators is challenging; thus we considered that pathogen effector proteins may have untapped use as components for predictably and systematically engineering signalling pathways. Here we use the effector proteins OspF and YopH to modulate kinase signalling pathways in yeast and in human primary T cells.
We first introduced OspF into yeast. As reported 10 , overexpression of OspF led to growth inhibition under standard conditions, hyperosmotic stress conditions ( Fig. 1b ) and cell-wall-damaging conditions ( Supplementary Fig. 1a ). OspF contains a canonical docking peptide at its amino (N) terminus that allows it to bind several MAPKs in yeast 11 . We found that expression of an OspF mutant lacking its native docking peptide (DN-OspF) yielded normal growth behaviour under all conditions ( Fig. 1b and Supplementary Fig. 1a ). Next we tested whether DN-OspF could be redirected to a specific pathway by tagging the protein with a leucine zipper heterodimerization motif, and fusing the complementary interacting motif to Pbs2, the scaffold protein that organizes the osmolarity MAPK pathway. This targeted version of DN-OspF only showed a growth defect under high salt conditions, showing that OspF activity could be engineered to inhibit a specific MAPK ( Fig. 1b) .
To explore re-targeting OspF to specific pathways further, we engineered yeast strains in which DN-OspF was selectively targeted to either the osmolarity MAPK complex or the mating MAPK complex (by targeting it to the mating pathway scaffold protein, Ste5) ( Fig. 1c ). Targeting of DN-OspF to the Pbs2 inhibited the osmolarity response but not the mating response. Conversely, when DN-OspF was targeted to Ste5, only the mating response was inhibited. Thus, the inhibitory activity of this effector could be selectively aimed at one of several MAPK pathways in the same cell.
One of the unique aspects of OspF is that it catalyses an irreversible inactivation of MAPKs (unlike reversible dephosphorylation by a phosphatase). Thus MAPK activity can only be restored through new protein synthesis, which has a much slower timescale than re-phosphorylation ( Fig. 2a, b ). This longer timescale would be expected to lead to an extended refractory period after OspF action, during which the targeted MAPK pathway could no longer respond to subsequent stimuli.
Computational simulations indicated that a long refractory period could result in significant changes to the frequency-dependent behaviour of pathway response ( Supplementary Fig. 2 ). There is growing evidence that cells use frequency modulation of diverse molecular events to encode and transmit information 12, 13 . Our models indicated that with a negative feedback loop (that is, MAPK activity induced expression of OspF), pathway output would be dampened when input periods are long enough to accumulate significant amounts of the negative effector but shorter than the refractory period (Supplementary Fig. 2 ).
To test if OspF could be used to filter frequency dependent inputs, we constructed a synthetic negative feedback loop in the yeast osmoresponse pathway by expressing OspF targeted to the osmo-response signalling complex (DN-OspF-zipper) from the Hog1 responsive promoter, pSTL1 ( Fig. 2c ). As a comparison, we also engineered an analogous synthetic feedback loop using a reversible Hog1 MAPK inhibitory protein-the yeast MAPK phosphatase, PTP2. Phospho-Hog1 translocation to the nucleus was used as a fast-timescale output reporter ( Supplementary Fig. 3 ) [14] [15] [16] . To measure integrated output over a longer timescale, we also measured a slower timescale transcriptional reporter-expression of mCherry from the pSTL1 promoter.
We found that the OspF-mediated negative feedback circuit altered the osmo-stress pathway response to intermediate frequency stimulation, but not to continuous stress or to high-frequency stimulation ( Fig. 2d and Supplementary Fig. 4a ). Furthermore, in the course of stimulating cells with pulses of KCl of varying length, we discovered that an input period of approximately 16 min (intermediate frequency) leads to highly divergent transcriptional responses ( Fig. 2d ). Examination of Hog1 nuclear import in the OspF feedback strain shows that after three pulses, the amount of Hog1 competent for nuclear localization has decreased to near zero, consistent with a model in which-in this timeframe-there is sufficient OspF to inactivate the bulk of the Hog1 population and now to render the cells refractory to further pulses of stimulation. The cells containing a PTP2 negative feedback circuit do not show this marked filtering at this frequency. With higher frequency stimulation (2 min period), the three strains also do not significantly differ from each other in response, presumably because there is inadequate activation time with each pulse to build up a sufficient concentration of effector 17 .
A broad frequency dependence analysis shows that the wild-type osmo-response pathway functions as a band-pass filter, with maximal response at intermediate frequencies, whereas the engineered pathway more closely resembles a low-pass filter, with maximal responses at low frequency ( Fig. 2e ). These distinct frequency filtering behaviours fit those predicted by computational simulations ( Supplementary  Fig. 2d ).
We then sought to test whether these bacterial effectors could be used to rewire signalling in immune cells. Human T cells are an attractive synthetic biology platform because they can be isolated from patients, genetically engineered ex vivo and then transferred back into patients to treat cancer and chronic infection 18, 19 . Although promising, the therapeutic application of engineered T cells carries risks of adverse side effects including inadvertent autoimmune-like attack of off-target host tissues 20, 21 . Thus mechanisms to control the specificity, amplitude and timing of T-cell function are critical to balance therapeutic action against off-target toxicity.
Both OspF and YopH can modify the T-cell receptor (TCR) pathway ( Fig. 3a) . OspF inactivates the MAPK extracellular signalregulated kinase (ERK), which is a central component of TCR signalling 4, 22 , whereas YopH dephosphorylates phospho-tyrosine, including the T-cell scaffold proteins LAT and SLP-76 (ref. 23 ). Constitutive expression of YopH and OspF in Jurkat T cells leads to severe inhibition of TCR activation, as measured by an NFAT transcriptional reporter 24 (Fig. 3a ) (as well as other reporters of T-cell activation; Supplementary Fig. 5a ). Expression of the catalytic dead versions of YopH and OspF had no effect on the TCR activation ( Supplementary  Fig. 5b ). In addition, we showed that these two effectors clearly target distinct steps of the T-cell activation pathway, because induction of the T cells with the combination of phorbol 12-myristate 13-acetate (PMA) and ionomycin, which activates the T cell downstream of the PLCc1-LAT/SLP76 dependent response, bypassed YopH inhibition 25 , but was sensitive to OspF inhibition ( Fig. 3a and Supplementary Fig. 5a 
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pathway at particular steps, much like a specific small-molecule inhibitor.
Given the ability of OspF and YopH to modulate T-cell responses, we sought to use these proteins to build circuits that could, in principle, improve the safety of therapeutic T cells. In adoptive T-cell therapy, a challenge is to limit over-activation or off-target activation of T cells that could lead to killing of host cells or to cytokine storm-a lifethreatening immune response. One approach is to incorporate a safety 'kill switch' [26] [27] [28] into the T cells, such as the herpes simplex virus thymidine kinase gene. This protein converts the pro-drug ganciclovir into an inhibitor of replication, thus killing cells expressing the gene. Although herpes simplex virus thymidine kinase is currently being tested in a phase III clinical trial for the treatment of graft versus host disease in bone marrow transplants, this strategy irreversibly destroys the engineered, adoptively transferred cells 29 . Thus, instead of killing the engineered cells, we sought to design circuits that would limit the amplitude of the T-cell response or to pause T-cell activity temporarily.
We first tested whether bacterial effectors could be used to limit the response amplitude of Jurkat T cells. Negative feedback loops can act to limit the maximal amplitude of a response 30 , so we engineered a library of negative feedback loops in which the OspF and YopH were expressed from a series of TCR-responsive promoters of varying strength (AP1 and NFAT) ( Fig. 3b and Supplementary Fig. 7) . For further tuning of feedback parameters, we also tagged effectors with degradation sequences (PEST motif) that reduce the half-life of the effectors. This series of negative feedback loops led to controlled reduction of the maximal response amplitude of T-cell activation (Fig. 3b) . Moreover, the amplitude could be tuned systematically by varying feedback promoter strength and effector stability ( Supplementary  Fig. 7b ). For example, expression of OspF from the strong feedback (pNFAT) promoter leads to a very low maximal response amplitude, but this effect could be systematically tuned by destabilizing the OspF effector with a PEST tag.
We also tested whether the bacterial effectors could be used to construct pause switches, which could transiently and reversibly disable T cells. We placed the effectors under the control of a tetracycline inducible promoter (pTRE), which allowed external control of the timing of effector expression with the addition of doxycycline. 
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Effectors were fused to a destabilization domain so that they would be rapidly degraded once doxycycline is removed. Using this system, we first showed that transient expression of bacterial effectors can inhibit TCR signalling after the pathway is activated in Jurkat T cells (Fig. 3c ). TCR signalling can be inhibited up to 6 h after activation using this approach ( Supplementary Fig. 8b ). Finally, we showed that engineered T cells can be subjected to cycles of TCR activation, paused with a short period of induced expression of the bacterial effector, and then reactivated after this pause ( Supplementary Fig. 8c ). We then tested the pause switch in a clinically important cell type for adoptive immunotherapy-primary human CD4 1 T cells (in contrast to the Jurkat T-cell line, which does not require cytokine or TCR activation to stimulate proliferation). We showed that when OspF is induced by the addition of doxycycline, both interleukin-2 (IL-2) release and cell proliferation were inhibited in a dose-dependent manner (Fig. 4b, c) . Activation of the TCR by anti-CD3/CD28 and antigen-presenting cells can also be inhibited by expression of OspF ( Supplementary Fig. 9a ). Moreover, after doxycycline is removed, IL-2 release and cell division recovers in 6-18 h (Fig. 4d, e ). Sustained exposure to doxycycline can inhibit T-cell activity over the course of several days (Fig. 4e ) without having any significant effect on cell viability ( Supplementary Fig. 9c ). Thus this work provides a proof of principle for the design of a simple 'pause' switch that could allow external control over the timing and level of T-cell activation and cytokine release, to minimize adverse events associated with adoptive immunotherapy such as cytokine storm.
Most work on bacterial pathogen effector proteins has the longterm aim of neutralizing the pathogens' infectious capabilities. We have shown, however, that bacterial effectors can also be valuable synthetic biology tools, because of their unique biochemical properties. We have used bacterial effectors to modulate MAPK signalling in yeast to generate novel time-dependent dynamics. We have also shown that bacterial effectors can be used to tune human TCR signalling dynamics flexibly, with potential application as safety switches for adoptive immunotherapy. The vast array of bacterial pathogen effector proteins, beyond those studied here, holds promise as a rich and important source of parts for the cellular engineering toolkit. 
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oil immersion lens. Image analysis for both nuclear Hog1-GFP import and pSTL1-mCherry expression was performed with custom MATLAB (Mathworks) software.
Human T-cell activation assay. Resting human primary CD4 1 cells (transduced with the pause switch constructs or untransduced) were pretreated with 200 ng ml 21 doxycycline for 6 h. Fifty thousand cells were placed in a 96-well plate with 200 ml human growth media with activation agents added (10 ng ml 21 PMA 1 0.5 mM ionomycin, magnetic Dynabeads coated with anti-CD3/anti-CD28 (beads:cells ratio, 0.3:1)). After 24 h of incubation at 37 uC, the released IL-2 in the supernatant was measured with a human IL-2 ELISA kit II (BD Biosciences). Cells labelled with CellTrace Violet dye (Invitrogen) were assayed by flow cytometry after incubation for 4 days to quantify cell proliferation.
METHODS
Yeast constructs and strains. All yeast constructs used in this study ( Supplementary Table 1 ) were cloned using a combinatorial cloning strategy on the basis of the type II restriction enzyme AarI developed by Peisajovich et al. 31 .
For the MAPK pathway specific inhibitory experiments, strains WP022 and WP116 were constructed from the W303-derived strain SP147 (Supplementary  Table 2 ) by tagging the carboxy (C) terminus of endogenous Pbs2 or Ste5 with leucine zipper, respectively. To construct WP039 for measuring the nuclear Hog1 accumulation, the C terminus of endogenous Hog1 in wild-type W303 strain was tagged with GFP using standard integration technique. For the visualization of the nucleus, a histone protein Htb2 was C-terminally tagged with mCherry, expressed from the ADH1 promoter, and integrated at TRP1 locus. Endogenous Pbs2 was tagged with a leucine zipper by PCR integration and was used in synthetic feedback loops. Synthetic effector gene cassettes were integrated at the LEU2 locus. Yeast promoters, terminator and the PTP2 gene were PCR amplified from Saccharomyces cerevisiae genomic DNA (Invitrogen). YopH gene was a gift from K. Orth. The OspF gene was synthesized by Integrated DNA Technologies. All yeast genomic integrations were confirmed by yeast colony PCR.
Yeast flow cytometry experiments. Analysis of the pathway-dependent fluorescent protein (GFP and mCherry) expression in yeast cells was performed with the BD LSRII flow cytometer (BD Biosciences) equipped with a high-throughput sampler. For each experiment, triplicate cultures were grown in synthetic complete media to early log phase (D 600 nm 5 0.1-0.2). At time 5 0, 1.5 mM of a-factor (GenScript) or 0.4 M of KCl were added into parallel cultures to induce separately the mating-specific or osmo-specific pathway response. For mating response, 100 ml aliquots were taken at time 5 0 and after 2 h of induction; for osmotic response, 100 ml aliquots were taken at time 5 0 and after 1 h of induction. Each 100 ml sample aliquot was immediately mixed with 100 ml of cycloheximide (10 mg ml 21 ) in 96-well plates to stop the protein synthesis. After incubating the samples at room temperature for 30 min in the dark to allow for the maturation of fluorescent proteins, the levels of fluorescence protein were determined by flow cytometry. For each read, 10,000 cells were counted, and the mean fluorescent density was calculated by Flowjo software (BD Biosciences) as the pathway output value, and the s.d. from triplicate experiments was indicated as the error bar. Yeast microfluidics, fluorescent microscopy and image processing. Microfluidic yeast cell culture was performed in Y04C plates with an ONIX flow control system (Cellasic) 32 . Cultures were grown to mid-log phase (D 600 nm 5 0.2-0.8) in synthetic complete media. Cells were diluted to D 600 nm 5 0.01 in 600 ml of fresh media and sonicated at a minimum set of 11% for 1 s using a Fisher Scientific model 500 sonicator with a 2 mm tip. Cells were loaded into the flow chamber precoated with concanavalin A and flowed over by synthetic complete media for more than 20 min before applying the square pulse sequence. Pulse stimulation with salt media was performed by ONIX FG flow control software (Cellasic) with the flow pressure of 8 pounds per square inch. Image acquisition was performed with a TE2000-E automated inverted microscope (Nikon) with Perfect Focus and 3100 oil immersion lens. Background subtraction was performed first on all fluorescence images using ImageJ (http://imagej.nih.gov). The subsequent image analysis for both nuclear Hog1-GFP import and pSTL1-mCherry expression was performed with custom MATLAB (Mathworks) software (developed by K.-Y. Lau from C. Tang's laboratory at University of California San Francisco). For Hog1-GFP import analysis, cell boundaries were first determined from the bright-field differential interference contrast microscopy images. Cell nuclei were segmented by mCherrylabelled nuclear images. The nuclear and total cell GFP densities were calculated from the GFP fluorescent images. For pSTL1-mCherry expression, cell boundaries were determined the same way Hog1-GFP localization and mCherry densities were determined from the mCherry fluorescent images. For all frequency responses, a 210 min time course of pulse stimulation was performed and the maximum value of each time course was taken as the output of the stimulation frequency. The population average of more than 50-100 cells was determined for each single measurement, each experiment was repeated at least three times (see also Supplementary Fig. 3c, d ) and the s.d. was calculated with the three repeats.
Jurkat T-cell lines, plasmids and transfection. The Jurkat T cell with pNFAT-EGFP (neomycin resistant) stably integrated into the chromosome is a Weiss laboratory stock strain. All plasmids were made by using standard cloning techniques, AarI combinatorial cloning technique 31 and Gateway cloning technique (Invitrogen). See Supplementary Tables for more cloning detail. Jurkat cells were maintained in RPMI 1640 supplemented with 10% heatinactivated FBS (Invitrogen), extra L-glutamine (2 mM), penicillin, streptomycin and G418 (2 mg ml 21 , Invitrogen).
For transfection, Jurkat T cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS) and glutamine (10G RPMI) for at least 1 day. Twenty million cells were spun down, washed once with 10G RPMI
